Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Times P. Managing and Treating Fever: A Guide to Nonprescription Antipyretics 2018. https://www.pharmacytimes.com/publications/issue/2018/February2018/managing-and-treating-fever-a-guide-to-nonprescription-antipyretics. Accessed 19 March 2020.
Chandler M. Global ibuprofen shortage hits UK supermarkets—with shelves left empty. 2019. https://www.mirror.co.uk/news/uk-news/global-ibuprofen-shortage-hits-uk-20465178. Accessed 1 April 2020.
News B. Coronavirus and ibuprofen: separating fact from fiction. 2020. https://www.bbc.com/news/51929628. Accessed 1 April 2020.
Today U. Fact check: does using ibuprofen when you have coronavirus make symptoms worse? 2020. https://www.usatoday.com/story/news/factcheck/2020/03/18/fact-check-coronavirus-and-ibuprofen-do-nsaids-make-coronavirus-worse/2865866001/. Accessed 1 April 2020.
News N. Concerned about taking ibuprofen for coronavirus symptoms? Here's What Experts Say. 2020. https://www.npr.org/sections/health-shots/2020/03/18/818026613/advice-from-france-to-avoid-ibuprofen-for-covid-19-leaves-experts-baffled. Accessed 1 April 2020.
Willsher K. Anti-inflammatories may aggravate Covid-19, France advises. 2020. https://www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. Accessed 1 April 2020.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
Agency EM. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020. https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. Accessed 3 May 2020.
Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. medRxiv. 2020. https://doi.org/10.1101/2020.04.11.20061994
DRUG USF. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. Accessed 3 May 2020.
GOV.UK. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19). 2020. https://www.gov.uk/government/news/commission-on-human-medicines-advice-on-ibuprofen-and-coronavirus-covid-19. Accessed 3 May 2020.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20. PMID: 31996437; PMCID: PMC7081895. https://doi.org/10.1128/JVI.00127-20
Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97–106.
Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults. Pharmacoepidemiol Drug Saf. 2005;14(4):257–66.
Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ. Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf. 2002;11(8):687–93.
Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–9.
Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):1–9.
Worl Health Organization WH. R&D Blueprint and COVID-19. 2020. https://www.who.int/teams/blueprint/covid-19. Accessed 12 June 2020.
Micallef J, Soeiro T, Jonville-Béra AP. French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology and COVID-19 infection. Therapies. 2020;75(4):355-362. https://doi.org/10.1016/j.therap.2020.05.003
Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–74.
ClinicalTrials.gov. LIBERATE Trial in COVID-19 (LIBERATE). 2020. https://clinicaltrials.gov/ct2/show/NCT04334629. Accessed 12 June 2020.
Smart L, Fawkes N, Goggin P, et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacol. 2020;28:1141–52. https://doi.org/10.1007/s10787-020-00745-z.
Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral Therapy. 2006;11(8):1021.
Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57(5):2231–42.
Zheng W, Fan W, Zhang S, Jiao P, Shang Y, Cui L, et al. Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. Cell Rep. 2019;27(6):1875-855.e5.
SafiDahaj F. RE: Response to the emerging novel coronavirus outbreak: British Medical Journal Publishing Group. 2020. https://www.bmj.com/content/368/bmj.m406/rapid-responses. Accessed 12 June 2020.
ClinicalTrials.gov. Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection (ENACOVID). 2020. https://clinicaltrials.gov/ct2/show/NCT04325633. Accessed 12 June 2020.